title: [Homocystein and cardiovascular risk: is dosage useful?].
abstract: Hyperhomocysteinemia represents an independent risk factor for atherothrombotic disease. Physiopathological mechanisms of accelerated progression of atherosclerosis in presence of hyperhomocysteinemia are complex. Herein we report a clinical case which emphasis the importance of screening elevated homocystein in the absence of conventional risk factors in patients who suffer from premature atherosclerosis.
authors.affiliation: Service de Médecine B, CHUV, Lausanne.
authors.forename: Ch
authors.initials: Ch
authors.lastname: Mathez
authors.forename: L
authors.initials: L
authors.lastname: Trueb
authors.forename: R
authors.initials: R
authors.lastname: Darioli
authors.forename: G
authors.initials: G
authors.lastname: Waeber
mesh_terms: D000328:Adult; D003324:Coronary Artery Disease / Q000097:blood* / Q000175:diagnosis / Q000235:genetics; D004252:DNA Mutational Analysis; D006580:Genetic Carrier Screening; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis / Q000235:genetics; D018455:Protein S Deficiency / Q000097:blood / Q000175:diagnosis / Q000235:genetics; D011516:Prothrombin / Q000235:genetics; D012008:Recurrence; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000175:diagnosis / Q000235:genetics
chemical_list: D006710:Homocysteine; D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2)